ПАТОГЕНЕЗ ТРОМБОЗА ЛЕВОГО ПРЕДСЕРДИЯ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ
И. В. Зотова
ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ, Москва
PDF

Ключевые слова

фибрилляция предсердий
тромбоз ушка левого предсердия
тромбоэмболические осложнения

Как цитировать

[1]
И. В. Зотова, ПАТОГЕНЕЗ ТРОМБОЗА ЛЕВОГО ПРЕДСЕРДИЯ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ, КМКВ, вып. 3, сс. 98-106, сен. 2020.
PDF

Аннотация

Тромбоз ушка левого предсердия является основным источником развития тромбоэмболических осложнений у больных с фибрилляцией предсердий. Накоплено множество данных о связи структурных особенностей левого предсердия, нарушений гемодинамики в предсердиях с риском образования тромба. У пациентов с фибрилляцией предсердий выявляются нарушения функционирования системы гемостаза, повышение уровня провоспалительных биомаркеров. В статье обсуждаются две основные теории патогенеза тромбоза – традиционная «аритмическая» и новая теория «предсердной кардиомиопатии». Согласно теории «предсердной кардиомиопатии» отсутствует прямая связь между фибрилляцией предсердий и развитием тромбоэмболических осложнений. Аритмия расценивается как одно важных, но не обязательных звеньев патогенеза тромбоза левого предсердия, что расширяет возможности использования антикоaгулянтов при других вариантах наджелудочковых аритмий.
PDF

Литература

1. Lip G.Y. Does atrial fibrillation confer a hypercoagulable state? //Lancet. –1995. –V. 346. - №. – 8986. – P. 1313-1314. doi: 10.1016/s0140-6736(95)92339-x.
2. Kleemann, T. et al. Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score //Eur J Echocardiogr. –2009. – V. 10. - №. -3. P. 383-388. doi: 10.1093/ejechocard/jen256.
3. Ogata T. et al. Left Atrial Size and Long-Term Risk of Recurrent Stroke After Acute Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation // J Am Heart Assoc. – 2017. – V. 6. - №. 8. – P. e006402. doi: 10.1161/JAHA.117.006402.
4. Chen Z.X. et al. Assessment of Left Atrial Appendage Size and Morphology by Enhanced Cardiac Computed Tomography in Patients with Non-valvular Atrial Fibrillation // Sichuan Da XueXueBao Yi Xue Ban. - 2017. – V. 48. - №. 6. – P. 911-916.
5. Wang F. et al. Predictive value of left atrial appendage lobes on left atrial thrombus or spontaneous echo contrast in patients with non-valvular atrial fibrillation // BMC CardiovascDisord. –2018. – V. 18. - №. 1. – P. 153. doi: 10.1186/s12872-018-0889-y.
6. Anselmino M. et al. Left atrial appendage morphology and silent cerebral ischemia in patients with atrial fibrillation // Heart Rhythm. –2014. – V. 11. - №. 1. – P. 2-7. doi: 10.1016/j.hrthm.2013.10.020.
7. Nedios S. et al. Left atrial appendage morphology and thromboembolic risk after catheter ablation for atrial fibrillation // Heart Rhythm. –2014. –V. 11. - №. 12. – P. 2239-2246. doi: 10.1016/j.hrthm.2014.08.016.
8. Zhao Y. et al. Relationship between left atrial appendage morphology and thrombus formation in patients with atrial fibrillation // International Journal of Cardiology. –2015. – V. 1. - №. 188. – P. 86-88. doi: 10.1016/j.ijcard.2015.04.033.
9. Akoum N. et al. Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation // J CardiovascElectrophysiol. – 2013. –V. 24. - №. 10. – P. 1104-1109. doi: 10.1111/jce.12199.
10. Daccarett M. et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation // J Am CollCardiol. –2011. –V. 57. - №. 7. – P. 831-838. doi: 10.1016/j.jacc.2010.09.049.
11. Sulzgruber P. et al. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke // European Heart Journal Cardiovascular Pharmacotherapy. –2019. –V. 5. - №. 3. – P. 171-180. doi: 10.1093/ehjcvp/pvz016.
12. Ling L. et al. Ratio of peak early to late diastolic filling velocity of the left ventricular inflow is associated with left atrial appendage thrombus formation in elderly patients with acute ischemic stroke and sinus rhythm // J Cardiol. - 2006. – V. 48. - №. 2. – P. 75-84.
13. Doukky R. et al. The value of diastolic function parameters in the prediction of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation // Cardiovasc Ultrasound. –2014. – V. 12. – P. 10. doi: 10.1186/1476-7120-12-10.
14. Kim T-H. et al. Left ventricular diastolic dysfunction is associated with atrial remodeling and risk or presence of stroke in patients with paroxysmal atrial fibrillation // Journal of Cardiology. –2016. –V. 68. - №. 2. – P. 104-109. doi: 10.1016/j.jjcc.2015.10.008.
15. Siller-Matula J.M. et al. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy //Int J Cardiol. – 2018. – V. 265. – P. 141-147. doi: 10.1016/j.ijcard.2018.04.093.
16. Sasaki S. et al. Left atrial strain as evaluated by two-dimensional speckle tracking predicts left atrial appendage dysfunction in patients with acute ischemic stroke // BBA Clinical. –2014. – V. 2. – P. 40-47. doi: 10.1016/j.bbacli.2014.09.004.
17. Leong D.P. et al. Left Atrial Dysfunction in the Pathogenesis of Cryptogenic Stroke: Novel Insights from Speckle-Tracking Echocardiography // J Am SocEchocardiogr. –2017. – V. 30. - №. 1. – P. 71-79.e1. doi: 10.1016/j.echo.2016.09.013.
18. Goldman M.E. et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study) // J Am SocEchocardiogr. – 1999. – V. 12. - №. 12. – P. 1080-1087. doi: 10.1016/s0894-7317(99)70105-7.
19. Ono K. et al. Motion of left atrial appendage as a determinant of thrombus formation in patients with a low CHADS2 score receiving warfarin for persistent nonvalvular atrial fibrillation // Cardiovasc Ultrasound. –2012. – V. 10. - P. 50. doi: 10.1186/1476-7120-10-50.
20. Kumagai T. et al. Risk factors for left atrial thrombus from transesophageal echocardiography findings in ischemic stroke patients // Fukushima J Med Sci. –2014. – V. 60. - №. 2. – P. 154-158. doi: 10.5387/fms.2013-12.
21. Bernhardt P. et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging // J Am CollCardiol. –2005. – V. 45. - №. 11. – P. 1807-1812. doi: 10.1016/j.jacc.2004.11.071.
22. Weymann A. et al. Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review // Med SciMonit Basic Res. –2017. – V. 23. – P. 97-140. doi: 10.12659/MSMBR.902558.
23. Wu N. et al. Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: a systematic review and meta-analysis // Can J Cardiol. –2015. – V. 31. - №. 3. – P. 278-286. doi: 10.1016/j.cjca.2014.12.002.
24. Maehama T. et al. Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation // J Cardiol. –2010. – V. 56. - №. 1. – P. 118-124. doi: 10.1016/j.jjcc.2010.03.006.
25. Roldan V. et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation // J ThrombHaemost. –2012. – V. 10. - №. 8. – P. 1500-1507. doi: 10.1111/j.1538-7836.2012.04812.x.
26. Hu X.F. et al. Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation //ClinCardiol. –2018. – V. 41. - №. 1. – P. 34-38. doi: 10.1002/clc.22844.
27. Wallentin L. et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial // Circulation. –2014. – V. 130. - №. 21. – P. 1847-1858. doi: 10.1161/CIRCULATIONAHA.114.011204.
28. Yalcin M. et al. Neutrophil-lymphocyte ratio may predict left atrial thrombus in patients with nonvalvular atrial fibrillation // ClinApplThrombHemost. –2015. – V. 21. - №. 2. – P. 166-171. doi: 10.1177/1076029613503398.
29. Saliba W. et al. Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study // J ThrombHaemost. –2015. – V. 13. - №. 11. – P. 1971-1979. doi: 10.1111/jth.13006.
30. Spronk H.M. et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation // Eur Heart J. –2017. – V. 38. - №. 1. – P. 38-50. doi: 10.1093/eurheartj/ehw119.
31. Boriani G. et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring // Stroke. –2011. – V. 42. - №. 6. P. 1768-1770. doi: 10.1161/STROKEAHA.110.609297.
32. Kamel H. et al. Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model // Stroke. –2016. – V. 47. - №. 3. – P. 895-900. doi: 10.1161/STROKEAHA.115.012004.
33. Gorenek B. et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and SociedadLatinoamericana de EstimulaciónCardíaca y Electrofisiología (SOLEACE) // EP Europace. –2017. – V. 19. - №. 9. – P. 1556-1578. doi: 10.1093/europace/eux163.
34. Brambatti M. et al. Temporal relationship between subclinical atrial fibrillation and embolic events // Circulation. –2014. – V. 129. - №. 21. – P. 2094-20999. doi: 10.1161/CIRCULATIONAHA.113.007825.
35. Martin D.T. et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices // Eur Heart J. –2015. – V. 36. - №. 26. – P. 1660-1668. doi: 10.1093/eurheartj/ehv115.
36. Larsen B.S. et al. Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation // J Am CollCardiol. –2015. – V. 66. - №. 3. – P. 232-241. doi: 10.1016/j.jacc.2015.05.018.
37. Himmelreich J.C.L. et al. Frequent premature atrial contractions are associated with atrial fibrillation, brain ischaemia, and mortality: a systematic review and meta-analysis // EP Europace. –2019. – V. 21. - №. 5. – P. 698-707. doi: 10.1093/europace/euy276.
38. Arnar D.O. et al. Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS) // EP Europace. –2019. – euz046.doi: 10.1093/europace/euz046.